Goldman Sachs Downgrades Agios Pharma (AGIO) to Neutral

Goldman Sachs downgraded Agios Pharma (NASDAQ: AGIO) from Buy to Neutral with a price target of $76.00 (from $75.00).

Analyst Terence Flynn said, "We are downgrading AGIO to Neutral from Buy as shares recently reached our 12-month price target. We continue to believe AGIO has a promising and innovative pipeline, but we now believe the market is adequately capturing the potential opportunities given the stage of development. AGIO also reported 3Q14 GAAP EPS of $0.10 vs. GS/consensus ($0.55)/($0.50) on higher partner revenues due to an accounting change and guided to YE14 cash of more than $220mn."

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.

Shares of Agios Pharma closed at $83.09 yesterday.

You May Also Be Interested In

• Freedom Broker Downgrades Karooooo Ltd. (KARO) to Hold
• U.S. Bancorp (USB) PT Raised to $74 at DA Davidson
• GE Aerospace (GE) PT Raised to $435 at UBS on Strong Demand